ReviewInternational journal of ophthalmology2026
Microglia in retinal vascular diseases: inflammatory mechanism and therapeutic target.
Review in International journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinal vascular diseases (RVDs) are leading causes of vision impairment and blindness, often associated with systemic diseases such as diabetes and hypertension. Despite treatment advancements, managing RVDs, particularly retinal vein occlusion (RVO), remains challenging due to the lack of a definitive cure and reliance on controlling complications. Microglia, the retina's resident immune cells, play a crucial role in maintaining retinal health, regulating inflammation, and modulating angiogenesis. In pathological conditions, microglia adopt heterogeneous and context-dependent activation states, contributing to both inflammatory injury and vascular repair. Studies suggest that modulating microglial activation and their secreted cytokines may provide novel therapeutic strategies for RVDs. This review examines the role of microglia in RVDs and their potential as therapeutic targets, exploring strategies such as inhibiting microglial activation, regulating pro-angiogenic factor secretion, and targeting specific signaling pathways. Future research should focus on understanding the specific roles of microglial subtypes, their contributions to disease progression, and developing targeted therapies for early diagnosis and treatment of RVDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.